Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus Target Price from Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $9.50.

SANA has been the subject of a number of research analyst reports. Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen upgraded Sana Biotechnology from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright dropped their price target on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Rodman & Renshaw initiated coverage on Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price target for the company. Finally, Weiss Ratings downgraded Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st.

Sana Biotechnology Stock Up 0.7%

SANA stock opened at $3.06 on Wednesday. The firm has a market capitalization of $851.57 million, a PE ratio of -3.29 and a beta of 2.17. Sana Biotechnology has a twelve month low of $1.63 and a twelve month high of $6.55. The stock has a 50-day simple moving average of $3.25 and a two-hundred day simple moving average of $3.91.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, equities research analysts anticipate that Sana Biotechnology will post -0.62 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in shares of Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after acquiring an additional 1,375,029 shares during the last quarter. Baillie Gifford & Co. lifted its position in Sana Biotechnology by 13.6% in the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after buying an additional 1,371,775 shares during the last quarter. Integral Health Asset Management LLC lifted its position in Sana Biotechnology by 33.3% in the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $7,100,000 after buying an additional 500,000 shares during the last quarter. Rafferty Asset Management LLC bought a new stake in Sana Biotechnology in the 3rd quarter worth approximately $951,000. Finally, Arizona State Retirement System lifted its position in Sana Biotechnology by 18.4% in the 4th quarter. Arizona State Retirement System now owns 47,342 shares of the company’s stock worth $193,000 after buying an additional 7,359 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.